Deal Watch: Gilead Ups Its Investment In CAR-T With Cell Design Buy
Astellas builds on a 2013 collaboration by acquiring Mitobridge. Ardelyx is partnering with Kyowa Hakko Kirin to bring tenapanor to market in Japan. Meanwhile, Depomed, Xoma and Bristol all offload programs before the end of the year.
You may also be interested in...
Asia Deal Watch: Juniper Licenses Asia-Pacific-Plus Rights To Kolon’s Osteoarthritis Cell Therapy
Plus deals involving Shionogi/NEC, Ji Xing/LENZ, Kyowa Kirin/Ardelyx, CR Pharma/Everest Medicine and Dr Reddy’s/Novartis.
Finance Watch: Biopharma Stocks See Big Post-IPO Jumps
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
TC BioPharm Plots Clinical-Stage Strategy For CAR-Modified Gamma Delta T-Cells
The UK cell therapy company has established cell therapy manufacturing facilities and plans clinical studies of CAR-modified gamma delta T-cells in cancer.